However, in our previous studies, we showed that longitudinal monitoring of KRAS-mutated ctDNA could help identify tumor dynamics in various treatments and revealed a significant correlation between KRAS-mutated ctDNA and CA19-9 levels in pancreatic cancer patients33,34. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.